|
Volumn 149, Issue 4, 2012, Pages 731-733
|
Network medicine strikes a blow against breast cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BIOLOGICAL MARKER;
DNA DAMAGING AGENT;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
PHOSPHOTRANSFERASE INHIBITOR;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTICLE;
BREAST CANCER;
CANCER CELL;
CANCER CHEMOTHERAPY;
DISEASE COURSE;
DNA DAMAGE;
DRUG SYNTHESIS;
DRUG TARGETING;
HUMAN;
PRIORITY JOURNAL;
TRIPLE NEGATIVE BREAST CANCER;
|
EID: 84860873858
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2012.04.014 Document Type: Short Survey |
Times cited : (47)
|
References (9)
|